臨床泌尿器科62巻3号

2008年03月発行

特集 前立腺肥大症のいま―古くて新しい疾患

前立腺肥大症の薬物療法におけるサブタイプ選択的α₁交感神経遮断薬

著者： 宍戸啓一¹ 嘉村康邦¹

所属機関： ¹福島県立医科大学医学部泌尿器科学講座

ページ範囲：P.191 - P.197

文献概要

要旨　近年，交感神経α₁-アドレナリン受容体のサブタイプ〔α_1A（α_1a），α_1B（α_1b），α_1D（α_1d）〕が同定され，その下部尿路における分布や機能が少しずつ明らかになってきた。そして前立腺のα₁-アドレナリン受容体サブタイプの分布に基づき，種々のα₁-アドレナリン受容体サブタイプ選択的遮断薬が開発され，前立腺肥大症治療薬として臨床の場で広く使用されるようになった。本稿では，前立腺を含む下部尿路臓器，神経，血管におけるα₁-アドレナリン受容体サブタイプ発現とその機能，前立腺肥大症患者の下部尿路症状に対する各選択的α₁遮断薬の効果について，最近の知見を交えて概説した。

参考文献

1）Gee WF, Holtgrewe HL, Blute ML, et al：1997 American urological association gallup survey：changes in diagnosis and management of prostate cancer and benign prostatic hyperplasia, and other practice trends from 1994 to 1997. J Urol 160：1804-1807, 1998

2）Bylund DB, Eikenberg DC, Hieble JP, et al：International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol Rev 46：121-136, 1994

3）Andersson KE：Storage and voiding symptoms：pathophysiologic aspects. Urology 62：3-10, 2003

4）Nasu K, Moriyama N, Fukasawa R, et al：Quantification and distribution of α1-adrenoceptor subtype mRNAs in human prostate：comparison of benign hypertrophied tissue and non-hypertrophied tissue. Br J Pharmacol 119：797-803, 1996

5）Chapple CR, Wyndaele JJ, Nordling J, et al：Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction（symptomatic BPH）. European Tamsulosin Study Group. Eur Urol 29：155-167, 1996

6）Lepor H：Phase Ⅲ multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology 51：892-900, 1999

7）Takei R, Ikegami I, Shibata K, et al：Naftopidil, a novel alpha 1-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human alpha 1-adrenoceptors. Jpn J Pharmacol 79：447-454, 1999

8）Yasuda K, Yamanishi T, Tojo M, et al：Effect of naftopidil on urethral obstruction in benign prostatic hyperplasia：assessment by urodynamic studies. Prostate 25：46-52, 1994

9）Yamanishi T, Yasuda K, Kamai T, et al：Single-blind, randomized controlled study of the clinical and urodynamic effects of an a-blocker（naftopidil）and phytotherapy（eviprostat）in the treatment of benign prostatic hyperplasia. Int J Urol 11：501-509, 2004

10）Ikemoto I, Kiyota H, Ohnishi Y, et al：Usefulness of tamsulosin hydrochloride and naftopidil in patients with urinary disturbances caused by benign prostatic hyperplasia：a comparative, randomized, two-drug crossover study. Int J Urol 10：583-594, 2003

11）Blue D, Alto P, Zinner N, et al：RO700004, a selective 1A-adrenoceptor antagonist, does not improve lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 167（Suppl）：265, 2002

-adrenergic receptor. Proc Natl Acad Sci USA 94：11589-11594, 1997

-adrenergic receptor subtypes in lower urinary tract symp-toms. BJU Int 86（Suppl 2）：11-22, 2000

14）Lepor H, Jones K and Williford W：The mechanism of adverse events associated with terazosin：an analysis of the veterans affairs cooperative study. J Urol 163：1134-1137, 2000

15）Persson K, Pandita RK, Sptlsbergen JM, et al：Spinal and peripheral mechanisms contributing to hyperactive voiding in spontaneously hypertensive rats. Am J Physiol 275：R1366-R1373, 1998

16）Smith MS, Schambra UB, Wilson KH, et al：Alpha1-adrenergic receptors in human spinal cord：specific localized expression of mRNA encoding alpha1-adrenergic receptor subtypes at four distinct levels. Mol Brain Res 63：254-261, 1999

adrenergic receptor antagonists on bladder activity in rats. Neurosci Lett 328：74-76, 2002

-adrenergic receptor subtypes in human detrusor. J Urol 160：937-943, 1998

19）Nomiya M and Yamaguchi O：A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders. J Urol 170：649-653, 2003

-adrenergic receptor antagonist tamsulosin. J Urol 173：657-661, 2005

21）Berger AP, Kofler K, Bektic J, et al：Increased growth factor production in a human prostatic stromal cell culture model caused by hypoxia. Prostate 57：57-65, 2003

22）Mitterberger M, Pallwein L, Gradl J, et al：Persistent detrusor overactivity after transurethral resection of the prostate is associated with reduced perfusion of the urinary bladder. BJU Int 99：831-835, 2007

23）Das AK, Leggett RE, Whitbeck C, et al：Effect of doxazosin on rat urinary bladder function after partial outlet obstruction. Neurourol Urodyn 21：160-166, 2002

24）Ishihama H, Momota Y, Yanase H, et al：Activation of alpha 1D adrenergic receptors in the rat urothelium facilitates the micturition reflex. J Urol 175：358-364, 2006

25）Djavan B, Chapple C, Milani S, et al：State of the art on the efficacy and tolerability of alpha 1-adrenoceptor antagonist in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 64：1081-1088, 2004

26）Kawabe K, Yoshida M, Homma Y：Silodosin Clinical Study Group：Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia：results of a phase Ⅲ randomized, placebo-controlled, double-blind study in Japanese men. BJU Int 98：1019-1024, 2006

27）Hisasue S, Furuya R, Itoh N, et al：Ejaculatory disorder caused by alpha-1 adrenoceptor antagonists is not retrograde ejaculation but a loss of seminal emission. Int J Urol 13：1311-1316, 2006

28）Goktas S, Kibar Y, Kilic S, et al：Recovery of abnormal ejaculation by intermittent tamsulosin treatment. J Urol 175：650-653, 2006

29）Oshita T, Ohashi Y, Inamura M, et al：Incidence of intraoperative floppy iris syndrome in patients on either systematic or topical α1-adrenoceptor antagonist. Am J Opthalmol 143：150-151, 2007